Savara Inc. (SVRA)
SVRA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1160308/000095017022005045/0000950170-22-005045-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SVRA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001160308 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2020
| Line | Value |
|---|---|
| Revenue | $257K |
| Net income | -$49.6M |
| Operating income | -$49.3M |
| Net margin | -19305.4% |
| Operating margin | -19182.9% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $22.9M |
| Total assets | $97.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3833.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $29.8M cash; operating cash flow -$32.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 220,623,511 (2026-11-09); 203,467,845 a year earlier; 135,341,024 three years earlier. | Cover page 2026-11-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | RSM US LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$43.0M | -$42.5M | $29.8M | $30.2M | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$40.2M | -$29.7M | $41.8M | $30.1M | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$37.3M | -$33.0M | $38.8M | $30.1M | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | Not filed | -$32.2M | -$25.1M | $33.2M | $29.9M | Needs four quarters | 10-K 2026-03-13 |
| Q3 2025 2025-09-30 | Not filed | -$29.6M | -$22.5M | $16.3M | $29.8M | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | Not filed | -$30.4M | -$26.3M | $17.4M | $29.7M | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2025 2025-03-31 | Not filed | -$26.6M | -$27.2M | $19.6M | $29.5M | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2024 2024-12-31 | Not filed | -$29.0M | -$23.3M | $15.1M | $26.6M | Needs four quarters | 10-K 2026-03-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-10-30 |
| Latest annual report | 10-K | 2026-03-13 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-06-08 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.9% |
| 1 month | -2.9% |
| 3 months | -12.0% |
| Year to date | -23.1% |
| 1 year | +8.9% |
| From 52-week high | -33.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| JBIO | Jade Biosciences Inc. | $15.34 | -4.99% | $975.3M |
| MLTX | MoonLake Immunotherapeutics | $11.73 | -6.16% | $998.3M |
| VSTM | Verastem Inc. | $7.70 | -5.87% | $970.3M |
| CYRX | CryoPort Inc. | $19.80 | -0.45% | $1.0B |
| SPTX | Seaport Therapeutics Inc. | $19.12 | -4.30% | $1.0B |
| MTRI | Mentari Therapeutics Inc. | $19.87 | +6.83% | $1.0B |
| AKTS | Aktis Oncology Inc. | $16.16 | -2.77% | $901.7M |
| CRVS | Corvus Pharmaceuticals Inc. | $10.60 | -0.38% | $894.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier